

**From:** Steele, Matthew  
**Sent:** Tuesday, October 25, 2016 2:09 PM  
**To:** nadine\_margaretten@merck.com  
**Cc:** Sweeney, Colleen; Khurana, Taruna  
**Subject:** STN 125592 IR

Hi Nadine, we have another IR for this STN. Similar to our recent request on the primary endpoint analyses:

In study MT-06 (P015), you indicate that the key secondary efficacy endpoint analyses were based on a linear mixed effect model and performed on the full analysis set (FAS) using a multiple imputation strategy for missing data (dataset denoted as FAS-MI). Please provide the percent treatment difference relative to placebo with the 95% confidence interval for the key secondary efficacy endpoints using the FAS-MI population.

As always, please do not hesitate to contact us with any questions.

Matthew Steele, PhD  
LCDR, US Public Health Service  
Team Leader, RRB-1  
FDA/CBER/OVRR/DVRPA  
Phone: (301)796-2640  
Fax: (301)402-0004

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to addressee, you are hereby notified that any review, disclosure, dissemination, copying or other action based on the content of this communication is not authorized. If you received this document in error, please immediately notify the sender by e-mail or phone.